Business
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world's most influential scientific meeting in the lung cancer field, taking place Sept
About this update from Nanjing Leads Biolabs Co., Ltd. Class H
[{"type":"text","content":"NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world's most influential scientific meeting in the lung cancer field, taking place September 12–15, where Leads Biolabs will present breakthrough efficacy data based on an expanded patient cohort compared to the previously reported 18-patient dataset.","length":733,"tagName":"p"},{"type":"text","content":"Previously reported early-stage NSCLC data showed that Opamtistomig combined with chemotherapy achieved a compelling objective response rate (ORR). With extended follow-up, deepening tumor responses and durable tumor shrinkage were observed across multiple subgroups, including immunotherapy-pretreated non-squamous NSCLC, first-line non-squamous NSCLC, and first-line squamous NSCLC.","length":384,"tagName":"p"},{"type":"text","content":"At WCLC 2026, the Company will present updated data demonstrating high response rates and continuously deepening tumor shrinkage of Opamtistomig in an expanded patient population, along with a safety profile consistent with previous findings. These results further validate the safety breakthrough enabled by conditional 4-1BB activation via the X-body platform and highlight Opamtistomig's differentiated clinical advantages in first-line NSCLC.","length":450,"tagName":"p"},{"type":"text","content":"Opamtistomig's potential as an IO 2.0 pan-tumor backbone therapy is being validated in three key dimensions—broad antitumor activity, long-term survival benefit trends, and a safety profile comparable to PD-(L)1 inhibitors: its clinical development spans 13 solid tumor indications, demonstrating first- or best-in-class potential in multiple tumor types, including NSCLC, extrapulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), and biliary tract cancer (BTC); clear survival benefit trends have been observed in multiple indications, with potential to translate into long-term efficacy benefits with conti...